Electronic Triggers: Microhematuria Trigger

NCT05011253 | Completed

• 1 other identifier: QI-MH
• Study Type: interventional
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.

Conditions

Hematuria

Outcome Measures

Primary Outcomes (1)

• Evaluation rate

  Urology evaluation with cystoscopy and appropriate imaging

  180 days of alert

Study Arms (2)

Intervention

EXPERIMENTAL

The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.

Other: Electronic Trigger Microhematuria Alert

Control

NO INTERVENTION

The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)

Interventions

Electronic Trigger Microhematuria Alert OTHER

To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Intervention

Eligibility Criteria

• Age: 35 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older
• + RBC on Urinalysis
• Urinalysis sent during an outpatient encounter
• any of the following: 60 years of age or older; RBC \> 25; current or prior tobacco use; Gross Hematuria

You may not qualify if:

• Under 35 years of age
• Cystoscopy within 1 year prior to Urinalysis
• Nitrite positive AND Leukocyte Esterase positive
• Nitrite positive AND \>100 WBC
• Leukocyte Esterase positive AND \>100 WBC
• Know GU cancer diagnosis
• Urinalysis ordered by urology provider

Sponsors & Collaborators

• NYU Langone Health: lead

Study Sites (1)

NYU Langone

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Hematuria

Condition Hierarchy (Ancestors)

Urination Disorders; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Saul Blecker, MD

  NYU Langone Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: SCREENING
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 16, 2021
• First Posted: August 18, 2021
• Study Start: October 6, 2021
• Primary Completion: December 6, 2021
• Study Completion: June 6, 2022
• Last Updated: July 14, 2022

Record last verified: 2022-07

Locations

US (1)